Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioactive Magnesium Silicate Activating Myocardial Energy Metabolism For Infarcted Myocardium Repair.

Exploration (Beijing, China)·2026
Same author

In Situ Synthesis of Rapid Hemostatic Zeolite/Gauze Composites on Pre-Seeded Gauze.

ACS applied bio materials·2026
Same author

Corrigendum to "Liquiritigenin targets transferrin receptor to potentiate ferroptosis sensitivity in colorectal cancer cells" [Phytomedicine. 154 (2026) 158057].

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Nitrate contamination in a karst aquifer affected by acid mine drainage during a storm event: Insights from stable isotopes and hydrochemical tracers.

Journal of hazardous materials·2026
Same author

Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma.

Neuro-oncology·2026
Same author

Ca<sup>2+</sup>-Crosslinked Alginate Network Attenuates Starch Digestibility and Postprandial Glycemic Response in Rice Starch Gels.

Foods (Basel, Switzerland)·2026
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.

Paddy Ssentongo1, Emma G Guare2, Chen Song1

  • 1Division of Infectious Diseases, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.

Current Oncology (Toronto, Ont.)
|March 27, 2026
PubMed
Summary
This summary is machine-generated.

Infections frequently complicate teclistamab treatment for multiple myeloma, often leading to therapy discontinuation. Proactive infection management is crucial for patients receiving this therapy.

Keywords:
BCMAbispecific antibodyimmunotherapy complicationsinfectionmultiple myelomareal-world datateclistamab

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: Mar 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Teclistamab, a bispecific antibody targeting B-cell maturation antigen, is used for relapsed/refractory multiple myeloma.
  • While effective, teclistamab is linked to significant infectious complications.
  • Limited real-world data exists on the infection risk associated with teclistamab therapy.

Purpose of the Study:

  • To determine the incidence of infections in patients treated with teclistamab.
  • To analyze infection-related outcomes and identify potential risk factors.
  • To characterize the real-world safety profile of teclistamab regarding infections.

Main Methods:

  • Retrospective cohort study of relapsed/refractory multiple myeloma patients.
  • Data collected from January 1, 2023, to November 20, 2023, at a single center.
  • Analysis included infection incidence, severity, outcomes, and risk factors.

Main Results:

  • 19 patients received teclistamab; 11 (57.9%) developed 19 infections.
  • Common infections included bacteremia, bacterial infections, and respiratory viral infections; 2 CMV reactivations occurred.
  • Median infection grade was 3, with 78.9% being Grade ≥3. Infections led to treatment discontinuation in 10 patients.

Conclusions:

  • Infectious complications are frequent and occur early during teclistamab therapy.
  • Infections significantly drive treatment interruption and permanent discontinuation.
  • There is a critical need for proactive infection risk assessment and management strategies.